• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Central nervous system pharmacokinetics of high-dose cytosine arabinoside.

作者信息

Lopez J A, Nassif E, Vannicola P, Krikorian J G, Agarwal R P

出版信息

J Neurooncol. 1985;3(2):119-24. doi: 10.1007/BF02228887.

DOI:10.1007/BF02228887
PMID:4031970
Abstract

The cerebrospinal fluid (CSF) pharmacokinetics of cytosine arabinoside (Ara-C) was determined in 8 patients with metastatic cancer in the central nervous system. High dose (3 gm/M2) one-hour intravenous infusions of Ara-C were given with serial CSF sampling obtained from indwelling Ommaya reservoirs. CSF was analyzed by high pressure liquid chromatography. Mean Ara-C elimination half life of 140 minutes in CSF was eight times longer than that in plasma. The peak mean CSF concentration of Ara-C (2.1 micrograms /ml) was about 7% of the plasma concentration (30 micrograms/ml). A total of 28 treatment courses were administered with minimal hematopoietic, gastrointestinal and neurological toxicities. A schedule of administration of 2 high-dose treatments 12 hours apart repeated every two weeks should maintain cytotoxic CSF concentrations which could prove useful in the management of CNS leukemia and lymphoma.

摘要

相似文献

1
Central nervous system pharmacokinetics of high-dose cytosine arabinoside.
J Neurooncol. 1985;3(2):119-24. doi: 10.1007/BF02228887.
2
Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs.犬体内阿糖胞苷的血浆和脑脊液药代动力学
Cancer Chemother Pharmacol. 1991;29(1):13-8. doi: 10.1007/BF00686329.
3
Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid.剂量和给药方案对大剂量阿糖胞苷在血浆和脑脊液中药物动力学的影响。
J Clin Oncol. 1983 Sep;1(9):546-51. doi: 10.1200/JCO.1983.1.9.546.
4
Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia.急性白血病患者中,其代谢产物高剂量阿糖脲苷对大剂量阿糖胞苷药代动力学的影响。
J Clin Oncol. 1983 Dec;1(12):763-71. doi: 10.1200/JCO.1983.1.12.763.
5
Cerebrospinal fluid and plasma pharmacokinetics of high doses of 1-beta-D-arabinofuranosylcytosine in nonhuman primates.高剂量1-β-D-阿拉伯呋喃糖基胞嘧啶在非人灵长类动物中的脑脊液和血浆药代动力学
Cancer Res. 1983 Nov;43(11):5190-3.
6
Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside.
Cancer Chemother Pharmacol. 1992;29(3):173-7. doi: 10.1007/BF00686248.
7
Pharmacokinetics of nimustine, cytosine arabinoside, and methotrexate in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy.脑脊液灌注化疗期间尼莫司汀、阿糖胞苷和甲氨蝶呤在脑脊液中的药代动力学
Biol Pharm Bull. 2001 Apr;24(4):436-8. doi: 10.1248/bpb.24.436.
8
[High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].[大剂量阿糖胞苷治疗急性白血病和白血病性脑膜炎:临床方面及药代动力学]
Onkologie. 1985 Feb;8(1):26-32. doi: 10.1159/000215606.
9
Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C).大剂量阿糖胞苷(HD ARA-C)的临床结果及药代动力学
Cancer. 1982 Oct 1;50(7):1248-57. doi: 10.1002/1097-0142(19821001)50:7<1248::aid-cncr2820500705>3.0.co;2-5.
10
Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.高剂量和中剂量1-β-D-阿拉伯呋喃糖基胞嘧啶重复静脉给药后1-β-D-阿拉伯呋喃糖基胞嘧啶和1-β-D-阿拉伯呋喃糖基尿嘧啶的血浆和脑脊液药代动力学
Cancer Res. 1991 Aug 15;51(16):4141-5.

引用本文的文献

1
In vivo distribution of cerebrospinal fluid tracer in human upper spinal cord and brain stem.脑脊液示踪剂在人体上颈髓和脑干中的体内分布。
JCI Insight. 2023 Dec 8;8(23):e173276. doi: 10.1172/jci.insight.173276.
2
Oral cytarabine ocfosfate pharmacokinetics and assessment of leukocyte biomarkers in normal dogs.正常犬口服阿糖胞苷磷酸酯的药代动力学和白细胞生物标志物评估。
J Vet Intern Med. 2023 Nov-Dec;37(6):2429-2442. doi: 10.1111/jvim.16842. Epub 2023 Sep 5.
3
Treatment of leptomeningeal spread of NSCLC: a continuing challenge.非小细胞肺癌脑膜转移的治疗:一个持续存在的挑战。

本文引用的文献

1
Central nervous system toxicity of high-dose systemic cytosine arabinoside.大剂量全身应用阿糖胞苷的中枢神经系统毒性
Cancer. 1981 Dec 15;48(12):2577-82. doi: 10.1002/1097-0142(19811215)48:12<2577::aid-cncr2820481207>3.0.co;2-z.
2
Simple and rapid high-performance liquid chromatographic method for analysis of nucleosides in biological fluids.用于分析生物体液中核苷的简单快速高效液相色谱法。
J Chromatogr. 1982 Sep 10;231(2):418-24. doi: 10.1016/s0378-4347(00)81866-6.
3
Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C).
Curr Treat Options Oncol. 2012 Dec;13(4):491-504. doi: 10.1007/s11864-012-0206-4.
4
Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcome.血液系统恶性肿瘤导致的肿瘤性脑膜炎:药代动力学考量及优化治疗效果
Clin Investig (Lond). 2011 Oct;1(10):1391-1402. doi: 10.4155/cli.11.115.
5
Treatment and prophylaxis of hematologic malignancy in the central nervous system.中枢神经系统血液系统恶性肿瘤的治疗与预防。
Curr Treat Options Neurol. 2011 Aug;13(4):400-12. doi: 10.1007/s11940-011-0128-7.
6
Identification and characterization of mefloquine efficacy against JC virus in vitro.甲氟喹对JC病毒体外疗效的鉴定与表征
Antimicrob Agents Chemother. 2009 May;53(5):1840-9. doi: 10.1128/AAC.01614-08. Epub 2009 Mar 2.
7
Pharmacokinetic considerations in the treatment of CNS tumours.中枢神经系统肿瘤治疗中的药代动力学考量
Clin Pharmacokinet. 2006;45(9):871-903. doi: 10.2165/00003088-200645090-00002.
8
Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells.阿糖胞苷与克拉屈滨对阿糖胞苷耐药人淋巴细胞生长协同作用的定量分析。
J Cancer Res Clin Oncol. 2005 Sep;131(9):609-16. doi: 10.1007/s00432-005-0012-5. Epub 2005 Oct 20.
9
Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis.柔脑膜转移治疗中的全身化疗、鞘内化疗及症状管理
Curr Oncol Rep. 2003 Jan;5(1):29-40. doi: 10.1007/s11912-003-0084-9.
10
Intrathecal chemotherapy with antineoplastic agents in children.儿童鞘内注射抗肿瘤药物化疗
Paediatr Drugs. 2001;3(4):237-46. doi: 10.2165/00128072-200103040-00001.
大剂量阿糖胞苷(HD ARA-C)的临床结果及药代动力学
Cancer. 1982 Oct 1;50(7):1248-57. doi: 10.1002/1097-0142(19821001)50:7<1248::aid-cncr2820500705>3.0.co;2-5.
4
Pharmacokinetics and metabolism of cytosine arabinoside in the central nervous system.阿糖胞苷在中枢神经系统中的药代动力学与代谢
J Pharmacol Exp Ther. 1982 Jul;222(1):1-6.
5
Pharmacokinetics of continuous intravenous and subcutaneous infusions of cytosine arabinoside.
Blood. 1982 Jun;59(6):1351-3.
6
Effects of high-dose cytarabine.大剂量阿糖胞苷的作用
Clin Pharmacol Ther. 1982 May;31(5):669-74. doi: 10.1038/clpt.1982.93.
7
A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.大剂量1-β-D-阿拉伯呋喃糖基胞嘧啶治疗急性白血病和难治性淋巴瘤的初步研究:临床反应与药理学
Cancer Res. 1982 Apr;42(4):1587-94.
8
Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia.急性白血病患者中,其代谢产物高剂量阿糖脲苷对大剂量阿糖胞苷药代动力学的影响。
J Clin Oncol. 1983 Dec;1(12):763-71. doi: 10.1200/JCO.1983.1.12.763.
9
Cerebrospinal fluid and plasma pharmacokinetics of high doses of 1-beta-D-arabinofuranosylcytosine in nonhuman primates.高剂量1-β-D-阿拉伯呋喃糖基胞嘧啶在非人灵长类动物中的脑脊液和血浆药代动力学
Cancer Res. 1983 Nov;43(11):5190-3.
10
Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid.剂量和给药方案对大剂量阿糖胞苷在血浆和脑脊液中药物动力学的影响。
J Clin Oncol. 1983 Sep;1(9):546-51. doi: 10.1200/JCO.1983.1.9.546.